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Analysis of the relationship between disease activity
and damage in patients with systemic lupus
erythematosus—a 5-yr prospective study
T. Stoll, N. Sutcliffe1, J. Mach, R. Klaghofer2 and D. A. Isenberg1
Objective. To determine whether initial damage, disease duration, age, initial health status, average disease activity over
the 5 yr or an average medication score covering the follow-up period would predict an increase in damage in patients
with systemic lupus erythematosus (SLE) within the next 5 yr.
Methods. A 5-yr prospective longitudinal study of a cohort of 141 consecutive patients with SLE attending a specialist
lupus out-patient clinic in London from their ﬁrst assessment between July 1994 and February 1995. Disease activity
was assessed using the BILAG system, initial health status by the Medical Outcome Survey Short Form 20 with an extra
question about fatigue (SF-20þ) and damage by the SLICC/ACR Damage Index (SDI). Damage was reassessed 5 yr later.
Statistical analysis was carried out using multiple logistic regression analysis (logXact).
Results. One hundred and thirty-three female and eight male SLE patients (97 Caucasians, 16 Afro-Caribbeans, 22 Asians
and 6 others) were included, their age at inclusion was 41.1 12.5 yr and their disease duration 10.2 6.3 yr. The
mean measures at inclusion were: total BILAG 5.2 (range 0–17), total SDI 1.2 (0–7) and medication score 1.2 (0–3). Six
patients were lost to follow-up because they had moved. Of the remaining 135 patients total damage had increased in
40 patients and 10 patients had died. At the end of the study, at 4.63 0.19 yr, the total SDI had increased to 1.6 1.7.
Multiple logistic regression analysis revealed that death and increase in damage were strongly predicted by a high total disease
activity over the entire study period (P<0.001) as we had hypothesized. When the total BILAG score was replaced by
the average number of A-ﬂares the prediction of accrual of damage during the study period was again highly signiﬁcant
(P¼ 0.004).
Conclusions. In this ﬁrst prospective study of its type a highly signiﬁcant impact of total disease activity, as measured over
5 yr using the BILAG system, on the development of total damage was revealed. Moreover, these results provide further
proof of the validity of the SDI and support the BILAG concept of the A-ﬂares.
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There is increasing agreement that in order to capture the totality
of the effects of SLE upon a patient there is a need to ascertain the
level of disease activity (those potentially reversible impairments
that are amenable to therapy), damage (meaning irreversible,
permanent problems) and the patient’s own perception of their
health status. Major international attempts have been undertaken
in the past decade to demonstrate the reliability and validity of at
least some of the available disease activity indices (reviewed in [1,
2]). In contrast a single instrument was developed to assess damage
in patients with SLE [3], the SLICC Damage Index, which was
shown to be valid at the same time (March 1996) in Europe and in
Canada and the USA [4, 5]. Its reliability [6], as well as the validity
of single-organ damage scores (its renal, pulmonary, neuropsy-
chiatric, musculoskeletal, cardiovascular and peripheral vascular
scores), has been demonstrated [4, 7]. Since its acceptance and
approval by the American College of Rheumatology it has been
renamed the SLICC/ACR Damage Index (SDI) and is now widely
used. Although not disease speciﬁc the SF-36 has followed the SF-
20 as a widely accepted health status instrument to be used in SLE
patients [8–10].
In the main disease activity indices are of a global nature.
The complexity of systemic lupus erythematosus (SLE), how-
ever, means that these indices can provide at best a relatively
crude assessment of disease activity. Occasionally, paradoxical
situations can be identiﬁed in which, for example, a patient
in hospital with severe renal disease, but little else, could have a
lower global activity score than a patient with mild to modest
disease in several systems who was still able to work. In order
to capture the subtleties of disease activity in patients with SLE
the British Isles Lupus Assessment Group has established the
BILAG index. This index is based upon the principle of the
physician’s intention to treat with disease-modifying therapy,
such as high doses of corticosteroids or immunosuppressives [11].
The BILAG index distinguishes disease activity in eight organs
or systems. The BILAG index is reliable and its total score as
well as all its organ/system scores, even in numerical form, are
valid [1, 12, 13]. The importance of using organ/system scores in
addition to a total activity score has been demonstrated by the low
internal consistency of the total BILAG score (Cronbach’s
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¼ 0.35) also mirrored in a lack of statistically signiﬁcant
correlations among different organ/system activity scores [13].
Many groups have assessed SLE patients using the SLICC/
ACR Damage Index (SDI) in cross-sectional studies, but rather
sparse data are available on its longitudinal and long-term use
in real patients. Gilboe et al. [14] found that disease activity and
damage at baseline predicted increase in damage 2 yr later. To
our knowledge no prospective 4- or 5-yr follow-up data have been
published assessing disease activity over the study period
and looking at its impact on the increase in damage. Therefore,
in the present study we have determined prospectively over 5 yr
the relationship between disease activity and the development
of damage. Is there an obvious link between global disease activ-
ity and the development of permanent damage as expressed by
the total damage score or between the disease activity in one
organ/system and the accrual of the respective organ damage?
The aim of the present study was to investigate whether one of
the dimensions of the assessment in SLE patients (initial damage,
initial health status or disease activity during the whole follow-
up period) or possible contributors to damage besides SLE disease
activity such as age or drug side-effects (as assessed by a medi-
cation score during the whole observation period) would predict
an increase in damage within the next 5 yr.
We hypothesized that an increase in total damage would
be predicted by a high total disease activity during the follow-
up period in accordance to a study in paper patients [5]. We
expected the same to be true for the organ/system scores, e.g.
musculoskeletal disease activity during the whole study period
was expected to lead to more musculoskeletal damage after
5 yr as suggested by a cross-sectional study [7] and by Gilboe
et al.’s investigation [14]. As damage is recorded following the
diagnosis of SLE regardless of its attribution to the disease pro-
cess itself, drug side-effects or even comorbidity, it cannot be
ruled out that drug side-effects (as assessed by a medication score)
over the follow-up or age at diagnosis (a crude parameter for
comorbidity) would also contribute to an increase in damage.
Patients and methods
Study design
This was a prospective longitudinal study of a cohort of
141 consecutively attending British patients with SLE followed
up in a specialist lupus out-patient clinic. Their ﬁrst assessment
in the study occurred between July 1994 and February 1995.
Each patient met four or more of the revised classiﬁcation criteria
of the ACR for SLE [15]. These patients (representing approxi-
mately 70% of the patients with lupus under our care in 1995)
were followed-up until June 1999. At every out-patient attendance
a formal BILAG disease activity assessment was undertaken.
Patients were usually followed at 3-monthly intervals. In those
patients with quiescent SLE intervals could be prolonged up
to 6 months or in very rare cases up to 12 months. Every patient
was instructed to bring her/his appointment forward if she/he
felt to be in any danger of ﬂaring. At every out-patient visit a
medication score was also determined. Damage was assessed at
study entry and reassessed 5 yr later at a visit to the same out-
patient clinic in the summer of 1999. Besides disease activity and
damage further disease parameters were assessed (see below).
The assessments undertaken in this study were part of our
normal clinical assessments and were performed at a time
(1994–1999) when the hospital did not require us to seek
ethical committee approval for this type of study. The patients
involved were all informed about the study and all gave their
verbal consent to a project that involved them in no additional
time, inconvenience or venesection (altogether fulﬁlling the
declaration of Helsinki).
Measures of assessment
Disease activity. BILAG [11–13] includes a total of 86
items in eight organs or systems (general, mucocutaneous,
neurological, musculoskeletal, cardiovascular/respiratory, vascu-
litis, renal and haematological). Each item is scored as present
or absent within the previous month. For an item to be recorded
in any category the assumption is made that the problem is due
to lupus (thus a patient with concomitant bronchial asthma
would not have shortness of breath recorded if the clinician felt
it was due to the coincident disease). To obtain a global score,
BILAG component scores can be assigned numerical values: A¼ 9
(most active disease), B¼ 3 (intermediate activity), C¼ 1 (mild and
stable disease activity), D¼ 0 (inactive disease) and E¼ 0 (no
activity ever), resulting in a potential summed range from
0 to 72 points. This numerical score has been shown to be valid
[13]. Validity has been demonstrated for the hypothesis that an
organ/system score of 9 (A) represents a ﬂare (A-ﬂare) [16]. For the
analyses either the average scores per visit to the out-patient clinic
or the average number of ﬂares per visit were used.
SLICC/ACR Damage Index (SDI). Damage, i.e. irrevers-
ible impairment since onset of SLE, is usually deﬁned as a
clinical feature that has to be continuously present for at least 6
months to score. In addition some irreversible events such as a
myocardial infarction or a cerebrovascular accident score as
damage on their occurrence. The components have been reported
in detail elsewhere [4–7]. Brieﬂy, damage is deﬁned for 12 organ
systems: ocular (range 0–2), neuropsychiatric (0–6), renal (0–3),
pulmonary (0–5), cardiovascular (0–6), peripheral vascular (0–5),
gastrointestinal (0–6), musculoskeletal (0–7), skin (0–3), endocrine
(diabetes) (0–1), gonadal (0–1) and malignancies (0–2). Damage
over time can only be stable or increase, theoretically to a
maximum of 47 points.
MOS short form 20 with an additional question for
fatigue (SF-20þ). At the initial out-patient visit (i.e. on the
same day) the patients completed the MOS short form 20 with
an additional question for fatigue (SF-20þ) [17, 18]. The 20
questions of SF-20 comprise six sections: physical, role, social
functioning, mental health, health perception and pain. As
explained elsewhere, a further question about fatigue was
added and we multiplied the numerical rating scale (0–10) by 10
[7]. Most of the scale scores are scored so that higher scores mean
better health (range 0–100). Only the scores for fatigue and
pain have the opposite polarity so that 0 means not fatigued at
all or no pain [13, 17, 18].
The medication score. A medication score was determined
at each visit by the physician [19]. The medication score
ranged from 0 to 3 (0¼ neither prednisone nor immunosuppres-
sants, 1¼ prednisone 1–20mg/day, 2¼ prednisone>20mg/day,
3¼ immunosuppressants, regardless of steroid dose). The average
medication score per visit was used for the analyses.
Age at diagnosis, disease duration. The date at which
a patient fulﬁlled the fourth of the revised classiﬁcation criteria
established by the American College of Rheumatology [15]
was recorded as the date of diagnosis which allowed us to calculate
the age at diagnosis. Disease duration (yr) was calculated by
subtracting the date of entry into the study from the date of
diagnosis.
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Statistical analysis
Dependent variables. Outcome at 5 yr follow-up was
divided into two groups: no increase in total damage score or
increase in total damage score. Death was regarded as the
worst outcome and therefore included in the latter group. The
same was done for organ damage scores as outcome, but excluding
patients who had died. Organ damage scores were analysed only
if they had increased in more than nine patients (otherwise too
low a sample size would not have allowed statistically signiﬁcant
conclusions).
Independent variables. All the variables assessed at study
entry (initial damage, disease duration, age at diagnosis,
initial health status) and those being derived over the whole
study period (the average BILAG or the average number of
A-ﬂares and an average medication score) were used to predict
outcome. To predict increase in damage only the correspond-
ing disease activity score was used, e.g. total BILAG to predict
total damage or musculoskeletal disease activity to predict
musculoskeletal damage.
Analysis. The bivariate relationship between disease activity
and increase in damage was investigated in an explorative analy-
sis using Spearman’s rank correlation coefﬁcient. To determine
the impact of each independent variable on the dependent out-
come variables multiple logistic regression analysis was used
(program logXact for Windows). For group comparisons the
Mann–Whitney U-test was used.
Results
One hundred and thirty-three female and eight male SLE patients
(97 Caucasians, 16 Afro-Caribbeans, 22 Asians and 6 others)
were included, their age at inclusion was 41.1 12.5 yr and their
disease duration 10.2 6.3 yr (range 0.1 to 32 yr). Their initial
disease characteristics at the ﬁrst assessment and their damage
indices at the end of the study are shown in Table 1. At
the assessment 5 yr after inclusion six patients were lost to
follow-up because they had moved. Table 2 gives the disease
activity characteristics assessed over the entire study period, i.e.
the average BILAG disease activity scores, the average number
of A-ﬂares and the medication score per encounter of the
remaining 135 SLE patients. The number of encounters over
the 5 yr was on average 22 8 (ranging from 1 to 56). Average
disease activity was slightly lower than the initial one.
In 40 patients total SDI had increased and the mean damage
score was now 1.6 (range 0–8) (n¼ 125, see Tables 1 and 2:
damage scores at 5 yr are given in brackets). The damage score
had increased in 28 patients by 1, in eight patients by 2 and in
two patients by 3 and 4. Ten patients had suffered the maximum
‘damage’ as they had died during the follow-up period. Death
was caused by a cerebrovascular accident in three patients,
by cancer in two and by heart problems, bowel perforation, ‘old
age’, alcohol intoxication and CNS lupus followed by septicae-
mia in one patient each. The mean study duration in the
125 surviving patients was 4.63 0.19 yr (range 4.02 to 4.94 yr).
Tables 3 and 4 show which variables predicted a negative
outcome, i.e. death within the study period or an increase in
damage until the end of the study. Table 3 demonstrates the
results of the multiple logistic regression analysis when disease
activity was expressed as the average total BILAG score (per
visit). Table 4 shows the results of the multiple logistic regression
analysis when the average total number of BILAG A-ﬂares (per
visit) was entered instead as disease activity marker. Average
total BILAG score (P<0.001) (and the total number of ﬂares
per encounter, respectively,P¼ 0.004) were the strongest predictors
of an increase in total damage and death. Initial mental health
was the third signiﬁcant predictor of an increase in total damage
and death, although to a relatively weak extent (P¼ 0.03).
TABLE 1. Disease characteristics of the 141 SLE patients at the ﬁrst
assessment and, in brackets, damage scores 5 yr later (n¼ 125). The
organ damage score is only given if the number of patients with an
increase in damage score was >7
SDI/BILAG/SF-20þ/
medication scores Mean S.D.
Median;
range
Total damage 1.27 1.62
(1.6 1.7)
1; 0–7
(1; 0–8)
Musculoskeletal damage 0.27 0.56
(0.36 0.74)
0; 0–3
(0; 0–3)
Total BILAG score 5.2 3.8 4; 0–17
General BILAG 1 1.1 1; 0–9
Mucocutaneous BILAG 0.7 1.2 0; 0–9
Neurological BILAG 0.3 0.9 0; 0–9
Musculoskeletal BILAG 1.2 2 1; 0–9
Cardiovascular/respiratory BILAG 0.3 0.6 0; 0–3
Vasculitis BILAG 0.4 0.7 0; 0–3
Renal BILAG 0.3 0.9 0; 0–3
Haematological BILAG 1 1.2 0; 0–9
SF-20þ: physical functioning* 59 34 67; 0–100
SF-20þ: role functioning* 54 42 50; 0–100
SF-20þ: social functioning* 71 29 80; 0–100
SF-20þ: mental health* 64 22 68; 16–100
SF-20þ: health perception* 45 25 43; 0–100
SF-20þ: pain 53 35 50; 0–100
SF-20þ: fatigue 59 29 70; 0–100
Medication score 1.2 1.3 1; 0–3
*Lower scores always mean better health except for the SF-20þ scores
marked with an asterisk.
Musculoskeletal damage increased in 12 patients (for details see Table 6),
neuropsychiatric damage in nine, ocular and skin damage each in seven,
renal, peripheral vascular and gastrointestinal damage each in three,
pulmonary, cardiovascular damage, premature gonadal failure and
malignancy each in two patients. An increase in neuropsychiatric damage
meant cranial or peripheral neuropathy in three patients, seizures/
psychosis, cognitive impairment and cerebral vascular accident each in
two patients. Ocular damage in six patients was cataract and in one
retinal changes. Skin damage consisted of scarring chronic alopecia in six
patients and extensive scarring in one patient.
TABLE 2. Disease activity characteristics and medication score per
encounter over the whole study period (n¼ 135)
SDI/BILAG/SF-20þ/
medication scores Mean S.D. Median; range
Total BILAG score 4.5 2.3 4.2; 0.4–13
General BILAG 1 0.6 0.9; 0–3.9
Mucocutaneous BILAG 0.4 0.4 0.3; 0–1.9
Neurological BILAG 0.3 0.3 0.2; 0–2.1
Musculoskeletal BILAG 0.9 1 0.8; 0–9
Cardiovascular/respiratory BILAG 0.3 0.5 0.1; 0–2.1
Vasculitis BILAG 0.4 0.4 0.4; 0–1.5
Renal BILAG 0.2 0.5 0; 0–2.4
Haematological BILAG 0.9 0.8 0.9; 0–3.1
Total A-ﬂares 0.16 0.27 0; 0–1.6
General A-ﬂares 0.05 0.13 0; 0–0.8
Mucocutaneous A-ﬂares 0.02 0.09 0; 0–1
Neurological A-ﬂares 0.02 0.09 0: 0–0.8
Musculoskeletal A-ﬂares 0.02 0.07 0; 0–0.5
Cardiovascular/respiratory A-ﬂares 0.04 0.12 0; 0–0.6
Vasculitis A-ﬂares 0.006 0.03 0; 0–0.2
Renal A-ﬂares 0.001 0.02 0; 0–0.2
Haematological A-ﬂares 0.007 0.05 0; 0–0.4
Medication score 1.2 1.2 1; 0–3
The number of encounters over the 5 yr was on average 22 8 (ranging
from 1 to 56).
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Table 5 shows the disease activity characteristics of the 50
patients with an increase in total damage or death at 5 yr and of
those 85 with a stable damage score at follow-up. The strongest
differences between these two groups were found in disease
activity markers over the entire study period, i.e. in higher
total BILAG scores, higher haematological BILAG scores and
a higher total number of A-ﬂares in the patients with increas-
ing damage (P always <0.001). Moreover, higher initial muscu-
loskeletal damage scores were observed in the patients with
increasing total damage (P<0.001). After Bonferroni’s correction
all the other disease characteristics shown in Table 5 no longer
show any signiﬁcant statistical difference.
The only organ damage score with an increase in more
than seven patients was the musculoskeletal damage score
which increased in 13 lupus patients. Increases in other organ
damage scores were observed in 7 patients. Table 6 shows
that no variable predicted an increase in musculoskeletal damage
score in a statistically signiﬁcant way.
TABLE 5. Disease characteristics of the 50 patients with an increase in total damage or death and of those 85 with a stable damage score at follow-up
SDI/BILAG/SF-20þ/
medication scores
Patients with increase in damage,
mean S.D. (median; range) P value
Patients with stable damage,
mean S.D. (median; range)
Age at diagnosis (yr) 32 13 NS 31 9
Disease duration (yr) 12 7 * 9 6
Initial total damage score 1.7 2.0 (1; 0–10) * 1.0 1.3 (0; 0–5)
Initial musculoskeletal damage score 0.44 0.58 (0; 0–2) *** 0.16 0.53 (0; 0–3)
SF-20þ: physical functioningy 50 36 (50; 0–100) * 63 32 (67; 0–100)
SF-20þ: role functioningy 45 44 (38; 0–100) NS 58 41 (63; 0–100)
SF-20þ: social functioningy 69 30 (60; 0–100) NS 72 29 (80; 0–100)
SF-20þ: mental healthy 66 22 (68; 16–100) NS 64 22 (64; 20–100)
SF-20þ: health perceptiony 39 24 (39; 0–87) NS 48 25 (47; 0–100)
SF-20þ: pain 55 36 (75; 0–100) NS 52 36 (50; 0–100)
SF-20þ: fatigue 62 29 (70; 0–100) NS 58 30 (70; 0–100)
BILAG total score (average per encounter) 5.6 2.6 (5.3; 1.2–13) *** 3.9 1.8 (3.6; 0.4–8.1)
General BILAG (average per encounter) 1.2 0.8 (1.1; 0–3.9) * 0.9 0.5 (0.9; 0–2.5)
Mucocutaneous BILAG (average per encounter) 0.5 0.5 (0.3; 0–1.9) NS 0.4 0.4 (0.4; 0–1.9)
Neurological BILAG (average per encounter) 0.3 0.3 (0.2; 0–1.3) NS 0.3 0.3 (0.1; 0–9)
Musculoskeletal BILAG (average per encounter) 1.2 1.4 (0.9; 0–9) * 0.8 0.7 (0.7; 0–3.2)
Cardiovascular/respiratory BILAG (average per encounter) 0.5 0.6 (0.3; 0–2.1) * 0.2 0.4 (0.1; 0–2)
Vasculitis BILAG (average per encounter) 0.4 0.4 (0.4; 0–1.3) NS 0.4 0.3 (0.3; 0–1.5)
Renal BILAG (average per encounter) 0.3 0.5 (0; 0–2.4) NS 0.2 0.4 (0; 0–2.3)
Haematological BILAG (average per encounter) 1.3 0.8 (1; 0–3) *** 0.7 0.7 (0.7; 0–3.1)
Total number of A-ﬂares (average per encounter) 0.26 0.31 *** 0.11 0.22
General A-ﬂares (average per encounter) 0.1 0.19 ** 0.03 0.08
Mucocutaneous A-ﬂares (average per encounter) 0.03 0.15 NS 0.007 0.04
Neurological A-ﬂares (average per encounter) 0.03 0.07 NS 0.02 0.1
Musculoskeletal A-ﬂares (average per encounter) 0.03 0.1 NS 0.01 0.05
Cardiovascular/respiratory A-ﬂares (average per encounter) 0.05 0.12 NS 0.03 0.12
Vasculitis A-ﬂares (average per encounter) 0.008 0.04 NS 0.005 0.03
Renal A-ﬂares (average per encounter) 0.004 0.03 NS 0 0
Haematological A-ﬂares (average per encounter) 0.01 0.06 NS 0.005 0.04
Medication score (average per encounter) 1.5 1.8 (1.1; 0–3) * 1.1 1.2 (0.5; 0–3)
yLower scores always mean better health except for the SF-20þ scores marked with a dagger.
*¼P<0.05; **¼P<0.01; ***¼P<0.001; NS¼not signiﬁcant.
TABLE 3. Prediction of death or increase in total damage score 5 yr after
inclusion (n¼ 135) when disease activity was described using the average
of the total BILAG scores (per visit)
Disease variable Odds ratio 95% C.I. P
Total BILAG score
(average per encounter)
1.623 1.219–2.161 0.001***
Initial mental health (SF-20þ) 1.029 1.003–1.056 0.029*
Disease duration 1.063 0.988–1.144 0.104
Physical functioning (SF-20þ) 0.987 0.968–1.006 0.167
Only variables at a P level <0.2 are given. Variables entered into the
analysis were all the variables assessed at study entry (total damage,
disease duration, age at diagnosis, all the seven domains of SF-20þ) and
the average total BILAG and medication scores over the duration of
the study.
Exploratory analysis with statistically signiﬁcant bivariate correlations
between disease activity and increase in total damage over the 5 yr
duration of the study, n¼ 135 (Spearman’s rank correlation coefﬁcients
are given): total BILAG 0.38**, haematological BILAG 0.33**,
cardiovascular/respiratory BILAG 0.27* (*¼P<0.05; **¼P<0.01;
***¼P<0.001).
TABLE 4. Prediction of death or increase in total damage score 5 yr after
inclusion (n¼ 135) when the average total number of BILAG A-ﬂares
(per visit) was entered as disease activity marker
Disease variable Odds ratio 95% C.I. P
Total number of A-ﬂares
(average per encounter)
18.588 2.5–138.2 0.004**
Initial mental health (SF-20þ) 1.03 1.003–1.058 0.028*
Initial physical functioning 0.985 0.966–1.003 0.107
Disease duration 1.058 0.985–1.136 0.124
Only variables at a P level <0.2 are given. Variables entered into the
analysis were all the variables assessed at study entry (total damage,
disease duration, age at diagnosis, all the seven domains of SF-20þ) and
the average number of A-ﬂares and medication scores over the duration
of the study.
Exploratory analysis with statistically signiﬁcant bivariate correlations
between disease activity and increase in total damage over the 5 yr
duration of the study, n¼ 135 (Spearman’s rank correlation coefﬁcients
are given): total number of A-ﬂares 0.27**; total number of
constitutional A-ﬂares 0.25* (*¼P<0.05; **¼P<0.01).
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Discussion
The present study examined prospectively the relationship
between disease activity and the development of damage in a
cohort of 141 British SLE patients attending a specialist lupus
out-patient clinic. The patients had suffered from SLE for
over 10 yr with a mean age of 41 yr at study entry. Over the
study period six patients had moved away and were lost to follow-
up. Of the remaining 135 patients total damage increased in
40 (29.6%). Ten patients had died.
In this study activity was assessed by the BILAG activity index
and damage by the SLICC/ACR damage index; both are
established and validated measures. Although most current
studies use the SF-36 to assess patient perception of disease,
its primacy was not established in 1994 when we started our study.
Furthermore we have shown a closer correlation between the
SF-20þ (used in this study) and the SF-36 [8].
Multiple logistic regression analysis revealed that death
and increase in damage were strongly predicted by a high total
disease activity over the entire study period (P<0.001) as we
had hypothesized. When total BILAG score was replaced by
the average number of A-ﬂares the prediction of accrual of
damage during the study period was again highly signiﬁcant
(P¼ 0.004). Also, when omitting the patients who died the analysis
revealed unchanged results as total BILAG scores (P<0.001)
and the number of A-ﬂares still strongly predicted (P¼ 0.008)
increases in total damage. Accordingly the patients with an
increase in damage during the study had higher total BILAG
scores and a higher number of A-ﬂares (P<0.001). Moreover,
our ﬁndings, the ﬁrst in adult patients with SLE, are in accord-
ance with those revealed in a shorter longitudinal study in
childhood-onset SLE which used the Systemic Lupus
Erythematosus Disease Activity Index (SLEDAI) to assess dis-
ease activity [20]. This paediatric SLE study found cumulative
disease activity over time to be the best predictor of damage
[20]. These ﬁndings reinforce the need to lower disease activity in
every single lupus patient and to support efforts to ﬁnd new
and more potent therapeutics and treatment strategies in SLE to
achieve this goal.
Initial mental health scores as assessed by SF-20þ predicted
to a statistically signiﬁcant extent an increase in total damage,
but unexpectedly, higher mental health scores (indicating better
health) predicted worse outcome. However, when comparing
the group with stable total damage to that with an increase
in total damage a signiﬁcant difference in initial mental health
scores was no longer present. Moreover, a previous study [21]
had shown ‘health perception’ and not ‘mental health’ scores
to predict increase in damage. Further studies are needed to
clarify the relationship between mental health scores and increase
in total damage.
Interestingly neither the average medication score over the
whole study period nor the age at diagnosis had predictive
value. As damage by deﬁnition is scored regardless of its
attribution to the disease process, comorbidity or drug side-effects,
these ﬁndings may indicate that SLE disease activity has a far
bigger impact on development of total damage than the other
two variables. However, age and the medication score used in
the present study are rather coarse substitutes for comorbidity
and drug side-effects, respectively. More detailed studies are
warranted to corroborate our results. However, undertaking
such studies will be very challenging, as for example, a patient
suffering from myocardial infarction may demonstrate: it can
be hard to attribute coronary artery disease solely to disease
activity (vasculitis), atherosclerosis caused by the traditional
cardiovascular risk factors or drug side-effects (e.g. by steroids).
The present study found no predictor of an increase in
musculoskeletal damage. There was a trend for age at diagnosis
to predict an increase in musculoskeletal damage. This may
be a hint that comorbidity has a stronger impact on musculo-
skeletal damage than on total damage. Musculoskeletal disease
activity was not signiﬁcantly correlated with the increase
in musculoskeletal damage (P¼ 0.18, Table 6). As we cannot
exclude a type 2 error (too small sample size), studies with
much bigger cohorts than the present one are warranted to
shed more light on damage accrual in each organ score.
From a cross-sectional study [7] we would expect a signiﬁcant
correlation between organ-speciﬁc disease activity over time and
the corresponding organ-speciﬁc damage accrual.
In the present prospective study the initial prevalence of
damage in at least one organ system in 56% of our SLE patients
is similar to that reported by Gorgos et al. [22] (59.8%) and the
mean initial damage score (1.2) is also similar to that of the
Montreal cohort of 1.3 with a mean disease duration of 15 yr [9].
In summary this prospective study revealed the highly
signiﬁcant impact of total disease activity, as measured over
5 yr using the BILAG system, on the development of total damage.
Moreover, these results provide further proof of the validity
of the SLICC/ACR Damage Index and support the BILAG
concept of the A-ﬂares.
The authors have declared no conﬂicts of interest.
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